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Abstract 
Background: Pregnant women with gestational diabetes mellitus (GDM) or type 2 diabetes mellitus (T2DM) are at 
increased risks of pre‑term labor, hypertension and preeclampsia. In this study, metabolic profiling of blood samples 
collected from GDM, T2DM and control pregnant women was undertaken to identify potential diagnostic biomarkers 
in GDM/T2DM and compared to pregnancy outcome.
Methods: Sixty‑seven pregnant women (21 controls, 32 GDM, 14 T2DM) in their second trimester underwent 
targeted metabolomics of plasma samples using tandem mass spectrometry with the Biocrates  MxP® Quant 500 Kit. 
Linear regression models were used to identify the metabolic signature of GDM and T2DM, followed by generalized 
linear model (GLMNET) and Receiver Operating Characteristic (ROC) analysis to determine best predictors of GDM, 
T2DM and pre‑term labor.
Results: The gestational age at delivery was 2 weeks earlier in T2DM compared to GDM and controls and correlated 
negatively with maternal HbA1C and systolic blood pressure and positively with serum albumin. Linear regression 
models revealed elevated glutamate and branched chain amino acids in GDM + T2DM group compared to controls. 
Regression models also revealed association of lower levels of triacylglycerols and diacylglycerols containing oleic and 
linoleic fatty acids with pre‑term delivery. A generalized linear model ROC analyses revealed that that glutamate is the 
best predictors of GDM compared to controls (area under curve; AUC = 0.81). The model also revealed that phosphati‑
dylcholine diacyl C40:2, arachidonic acid, glycochenodeoxycholic acid, and phosphatidylcholine acyl‑alkyl C34:3 are 
the best predictors of GDM + T2DM compared to controls (AUC = 0.90). The model also revealed that the triacylglyc‑
erols C17:2/36:4 and C18:1/34:1 are the best predictors of pre‑term delivery (≤ 37 weeks) (AUC = 0.84).
Conclusions: This study highlights the metabolite alterations in women in their second trimester with diabetes 
mellitus and identifies predictive indicators of pre‑term delivery. Future studies to confirm these associations in other 
cohorts and investigate their functional relevance and potential utilization for targeted therapies are warranted.
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Background
Gestational diabetes mellitus  (GDM) represents any 
degree of glucose intolerance with onset during preg-
nancy, regardless of whether treated by insulin or diet 
modification, or whether the condition persists after 
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pregnancy or not [1]. It does not exclude the possibility 
that unrecognized glucose intolerance may have ante-
dated or begun concomitantly with the pregnancy. GDM 
represents one of the most frequent complications in 
pregnancy [2]  with a prevalence range of 1–14% based 
on the diagnostic criteria, study population, ethnic-
ity and geographical location [3]. Its increasing preva-
lence has been attributed to the obesity epidemic among 
women of reproductive age [4]. GDM is diagnosed when 
glucose levels are elevated in the late second trimes-
ter [5]. Postpartum, 20% of women with GDM develop 
impaired fasting glucose  (IFG) and/or  impaired glu-
cose tolerance  (IGT), causing a 7.4 times higher risk of 
type 2 diabetes mellitus (T2DM) later in life compared 
to matching controls [6] and have an increased risk of 
cardiovascular disease (CVD) [7].  GDM has been asso-
ciated with adverse outcomes including pre-term deliv-
ery, preeclampsia, macrosomia, perinatal mortality and 
neonatal metabolic complications [8]. Spontaneous pre-
term delivery has been linked to poor glycemic control 
and parity [9–12], and is associated with a higher risk for 
neonatal intensive care unit admission due to respiratory 
failure and hypoglycemia [13]. It is also associated with 
chronic respiratory disease, ischemic heart disease and 
metabolic disorders [14–16]. These adverse outcomes of 
GDM have led clinicians to implement various strategies 
including fetal surveillance and induction of labor [17, 
18]. A number of risk factors for GDM have already been 
identified, including maternal age, family history of dia-
betes, pre-pregnancy obesity, and multiple pregnancies 
[19]. However, the metabolic pathways in GDM and/or 
pre-gestational T2DM in pregnancy and their relation-
ship to pregnancy outcomes is poorly understood. The 
identification of novel biomarkers may, therefore, have 
clinical diagnostic and therapeutic applications.
Discovery of metabolic mediators underlying dis-
ease progression in obesity-associated insulin resistance 
and T2DM [20] were facilitated by advancing metabo-
lomic tools such as mass spectrometry (MS) technolo-
gies, providing a better understanding of the etiology 
of the disease. The metabolic signature differentiating 
healthy controls from individuals at higher risk of T2DM 
included various carbohydrates (e.g. glucose and fruc-
tose), lipids (e.g. phospholipids, sphingomyelins, and 
triglycerides), and amino acids (branched-chain amino 
acids, aromatic amino acids, glycine, and glutamate) 
[20–22]. The pathophysiological changes that occur in 
pre-gestational T2DM and GDM are similar [23]. How-
ever, metabolomic studies aimed at predicting risk of 
GDM in pregnant women have shown inconsistent find-
ings, as some reported lower blood creatinine, trimeth-
ylamine-N-oxide, and betaine, while others reported 
elevated acetylcarnitines, bile acids, ketones, creatinine, 
carbohydrate, and other lipids and organic acids [24]. 
However, few studies have investigated the association 
between these metabolic markers and risk of pre-gesta-
tional T2DM and GDM-associated pathologies including 
pre-term labor [25].
The aim of this study was to perform targeted metabo-
lomics analysis of blood samples from pregnant women 
in their second trimester with pre-gestational T2DM, 
GDM or matching healthy controls to investigate the 
metabolic pathways underlying these pathologies and 
identify potential predictors of increased risk of pre-term 
labor.
Methods
Study design
This was a cross sectional study in 67 pregnant women 
(21 controls, 32 GDM, 14 T2DM) who were recruited 
during their second trimester at the antenatal clinic at 
The Women Wellness and Research Center of Hamad 
Medical Corporation (GDM and pre-gestational T2DM) 
in Doha, Qatar. Protocols were approved by Institutional 
Review Boards (IRBs) of the Hamad Medical Corpora-
tion (15101/15) and Weill Cornell Medical College in 
Qatar (15-00016). Demographics, anthropometrics and 
medical history data were collected including age, eth-
nicity, socio-economic background, vital signs, height, 
weight, menstrual cycle, period of infertility, medica-
tions, complications, comorbidities and family medical 
history. All pregnant women are screened in the first 
antenatal care visit using fasting blood glucose (FBG). 
If the FBG at the first visit is < 5.1  mmol/l (92  mg/dl); 
75  g oral glucose tolerance test (OGTT) is performed 
at 24  weeks’ gestation. The world health organiza-
tion (WHO) criteria [FBG ≥ 5.1  mmol/L (92  mg/dl), 
1  h post OGTT ≥ 10.0  mmol/L (180  mg/dl) or 2  h post 
OGTT ≥ 8.5  mmol/L(153  mg/dl)] is used to diagnose 
GDM. GDM patients were started on diet for 2  weeks 
with the aim of a FBG ≤ 5.3  mmol/l (95  mg/dl) and the 
2 h post prandial glucose being ≤ 6.8 mmol/l (120 mg/dl) 
in ≥ 80% of the readings. If more than 20% of the read-
ings were above target then Metformin therapy was 
implemented and increased incrementally followed by 
insulin supplementation when glucose targets were not 
achieved. Women with Type 2 diabetes were all treated 
with Metformin and basal-bolus insulin.
Laboratory tests included second trimester full blood 
count, biochemical profile and thyroid function tests. 
Blood samples were collected for the metabolomics 
analysis. All patients gave their written informed consent 
and the conduct of the study was in accordance with the 
International Council for Harmonisation Good Clini-
cal Practice and the Declaration of Helsinki. Pregnancy 
outcomes of gestational age at delivery, birthweight, 
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maternal weight, blood pressure and foetal outcome were 
recorded and collated with the metabolomic profile for 
all subjects who participated in the study.
Metabolomics
Targeted metabolomics of plasma samples was per-
formed using tandem mass spectrometry with the Bio-
crates  MxP® Quant 500 Kit (Biocrates, Innsbruck, 
Austria) at the Fraunhofer Institute for Toxicology and 
Experimental Medicine (ITEM). Lipids were measured 
by Flow Injection Analysis Tandem Mass Spectrometry 
(FIA-MS/MS) using a 5500  QTRAP® instrument (AB 
Sciex, Darmstadt, Germany) with an Electrospray ioni-
zation (ESI) source, and small molecules were measured 
by Liquid chromatography–mass spectrometry (LC–MS/
MS) using the same 5500  QTRAP® instrument as pre-
viously described [26]. Briefly, a 96-well based sample 
preparation device was used to quantitatively analyze the 
metabolite profile in the samples. This device consists 
of inserts that have been spotted with internal stand-
ards, and a predefined sample amount was added to the 
inserts. Next, a phenylisothiocyanate solution was added 
to derivatize some of the analytes (e.g. amino acids), and 
after the derivatization was completed, the target ana-
lytes were extracted with an organic solvent, followed by 
a dilution step. The obtained extracts were then analyzed 
by FIA-MS/MS and LC–MS/MS methods using multiple 
reaction monitoring (MRM) to detect the analytes. Data 
were quantified using appropriate MS software (Sciex 
 Analyst®) and imported into Biocrates MetIDQ™ soft-
ware for calculating analyte concentrations, data assess-
ment and compilation.
Statistical analysis
Demographics traits analysis: Statistical analyses were 
carried out using IBM SPSS version 25, R version 3.2.1 
and SIMCA 14 software (Umetrics, Sweden). Variables 
with skewed distributions were log transformed to ensure 
normality [27]. Comparisons were performed with 
t-test, Wilcoxon–Mann–Whitney and 1-way ANOVA as 
appropriate. Significance was defined as P ≤ 0.05. Non-
parametric tests were used for comparing ordinal or 
non-normal variables. Metabolomics data analysis: Prin-
ciple component analysis (PCA) was performed using 
R version 2.14, www.r-proje ct.org/. PCA revealed two 
main components (PC1 and PC2) that together captured 
24% of the variance in the data. Orthogonal partial least 
square discriminant analysis (OPLS-DA), implemented 
as part of the software SIMCA, was used to compare 
controls, GDM and T2DM groups. OPLS-DA is rec-
ommended in cases of regression where the number of 
explanatory variables is high, and where it is likely that 
the explanatory variables are correlated as it is the case 
in our data. All metabolites with a percentage of miss-
ing values greater than 50% were excluded from SIMCA 
analysis. Linear regression was performed to identify sig-
nificant metabolites differentiating study groups (controls 
vs GDM and T2DM) and (Controls vs GDM + T2DM) 
using the R statistical package (version 2.14, www.r-proje 
ct.org/) after correcting for age, BMI and principle com-
ponents (PC1 and PC2). Additionally, the gender interac-
tion effect was evaluated in ANOVA model that featured 
the same confounders. Contrast analysis was conducted 
using R package Emmeans to pinpoint the significance 
of effect per gender group. Function enrichment analy-
sis was performed using Fisher’s exact test by consider-
ing metabolites with a nominal p-value less than 0.1 from 
linear regression analysis. For a given biological function, 
the test assesses the probability of observing the associ-
ated nominally-significant metabolites from the linear 
model by pure chance. The biological categories tested 
for enrichment were provided by Biocrates and expanded 
manually by reference to the Human Metabolome Data-
base [28]. The Elastic net regularization of linear models, 
implemented in R package GLMNET, was used for selec-
tion of best predictors of clinical traits of interest to this 
study.
Results
General characteristics of participants
67 young (31.9 ± 5.7  years) overweight/obese 
(31.9 ± 6.9 kg/m2) pregnant women were included in this 
study. All included pregnancies resulted in single births. 
The T2DM women were older, had higher triacylglyc-
erols (TG), insulin and glycated haemoglobin (HbA1c), 
than body mass index (BMI)-matched controls and GDM 
(p < 0.05) (Table 1). Gestational age (GA) at delivery was 
on average 2  weeks earlier in T2DM than controls and 
GDM (p = 0.01) (Fig.  1a). GA at delivery was negatively 
correlated with HbA1c at baseline (R = − 0.34, p = 0.01, 
Fig.  1b) and with systolic blood pressure (SBP) at base-
line (R = − 0.34, p = 0.005, Fig.  1c), but positively corre-
lated with serum albumin (R = 0.39, p = 0.002, Fig.  1d). 
A regression model, incorporating explanatory variables 
(study group, HbA1c, SBP and serum albumin), indicated 
independent significant association of all four covariates 
with GA at delivery (study group: Beta = − 1.7, HbA1c: 
Beta: − 0.85, p = 0.01, SBP: Beta = − 0.04, p = 0.03, serum 
albumin: Beta = 0.06, p = 0.07) (Fig. 1). There was no dif-
ference in the proportion of male to female offspring was 
identified in the control group (11F vs 10 M). However, a 
significant interaction with offspring gender in the GDM 
and T2DM groups (p = 0.02) was identified, with a higher 
proportion of female than male offspring in GDM par-
ticipants (21F vs 11 M), whilst the opposite was true with 
T2DM participants (3F vs 11 M).
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A holistic view of the metabolic profile of GDM and T2DM
OPLS-DA comparing the multivariate metabolic pro-
file of controls, GDM and T2DM was used. OPLS-DA 
showed one class-discriminatory components account-
ing for 25% of the variation in the study group Y-variable. 
The Variable Importance in Projection (VIP) list empha-
sized the discriminatory effects of various glycerophos-
pholipids (phosphatidylcholine acyl-alkyl, PC.ae) such 
as PC.ae.C34.3, PC.ae.C34.2 and PC.ae.C42.3, triacyl-
glycerols (TG16.0/34.1, TG16.0/34.0 and TG18.1/32.0) 
and the amino acids, such as glutamate (Glu), aspartate 
(Asp), isoleucine (Ile) and arachidonic acid (AA) (Addi-
tional file 1: Table S1). The score plot in Fig. 2a indicates 
an x-axis that separates the controls from the GDM 
and T2DM. The corresponding loading plot, shown 
in Fig.  2b, indicates the aforementioned metabolites 
from the VIP list responsible for the groups’ separation. 
When GDM + T2DM (DM) were combined into one 
group, OPLS-DA showed one discriminatory compo-
nent accounting for 92% of the variation in the control/
combined DM group (Fig.  2c). The VIP list highlighted 
amino acids (Glu, leucine (Leu), valine (Val), Ile and Asp), 
triacylglycerols (TG16.0/34.2, TG16.0/34.1, TG18.2/32.0 
and TG18.1/32.0) and the glycerophospholipid (C34:3) 
(Additional file  1: Table  S2) [29], also indicated in the 
loading plot (Fig. 2d).
Metabolites differentiating controls from GDM + T2DM
Following multivariate analysis, univariate regression 
models were used to characterize metabolite-level asso-
ciations with GDM and DM (GDM + T2DM). The anal-
ysis revealed significant differences (false discovery rate 
(FDR) ≤ 0.05) in the levels of five metabolites between 
controls and T2DM (Additional file  1: Table  S3). These 
include four amino acids (Asp, Glu, citrulline (Cit) and 
Ile) and the glycerophospholipid (PC.ae.C34.3). A num-
ber of metabolites differentiated controls from GDM, 
but none reached FDR level of significance (Additional 
file  1: Table  S4). When comparing control vs DM, the 
linear model revealed a list of metabolites differentiating 
Fig. 1 Differences in gestational age (GA) at delivery in controls, gestational diabetes (GDM) and type 2 diabetes (T2DM) groups (a). Correlation 
of gestational age at delivery with baseline HbA1c (b) systolic blood pressure (c) and serum albumin (d). GA at delivery was compared among 
controls, GDM and T2DM groups using ANOVA. Pearson’s correlation was used to assess the relationship between GA at delivery and serum HbA1c, 
albumin and systolic blood pressure measured at third trimester. p‑value significance level of 0.05 (*) was used
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the two groups, with only Glu reaching FDR level of 
significance (FDR = 0.04) (Additional file  1: Table  S5). 
Table  2 lists the top 10 metabolites differentiating con-
trol and DM with their sub and super-pathways. Enrich-
ment analysis indicated that branched chain amino acids 
(BCAA) were elevated in DM compared to controls 
(p = 0.006) (Fig. 3).
Furthermore, offspring gender interaction analy-
sis revealed nominally significant association between 
metabolites and GDM + T2DM which were significantly 
different in pregnancies with male versus female off-
spring, including the triglycerides (18:2/31:0, 16:1/36:5, 
17:1/36:4, 16:0/35:3, 18:2/33:0), the amino acids/related 
(glutamine and ProBetaine) and the cholesterol ester 
CE18:3 (Additional file 2: Figure S1).
Metabolites associated with GA at delivery
Similarly, a linear model was used to assess the signifi-
cance of metabolites associated with GA at delivery. 
One hundred and eleven metabolites exhibited signifi-
cant association at FDR level of significance ≤ 0.05. The 
list of metabolites and their associated pathways are 
shown in Additional file  1: Table  S6. Among these, 22 
lipids were associated with gestational age at delivery at 
FDR ≤ 0.05 level of significance, including triacylglyc-
erols, diacylglycerols and bile acids (Table  3). Among 
Fig. 2 Orthogonal partial least square discriminate analysis (OPLS‑DA) comparing metabolites from controls, GDM and T2DM individuals (top) 
and controls versus combined GDM + T2DM (bottom). Score plots from the two models respectively showing one dimensional separation of all 
three classes (control, GDM, T2DM) (a) and two classes (controls and GDM + T2DM) (c). The corresponding loading plots showing top associated 
metabolites differentiating controls, GDM and T2DM (b) or GDM + T2DM vs Controls (d) groups
Table 2 Top ten metabolites differentiating controls from DM (GDM + T2DM) in women in their second trimester
Linear regression was performed to identify significant metabolites differentiating Controls from GDM + T2DM (DM) using the R statistical package after correcting for 
age, BMI and principle components (PC1 and PC2). Estimate (beta value), SE, standard error; FDR, False Discovery Rate
Metabolite Biochemical ID Super pathway Sub pathway Estimate SE P value FDR
Glu Glutamate Amino Acids Glutamate Metabolism 15.8 3.8 < 0.001 0.04
PC.ae.C34.3 Phosphatidylcholine C34:3 Lipid Glycerophospholipids − 1.5 0.4 < 0.001 0.13
Ile Isoleucine Amino Acids Leucine, Isoleucine and Valine Metabolism 10.9 3.3 0.002 0.25
Asp Aspartate Amino Acids Alanine and Aspartate Metabolism 1.3 0.5 0.005 0.29
Leu Leucine Amino Acids Leucine, Isoleucine and Valine Metabolism 14.8 5.7 0.011 0.29
Val Valine Amino Acids Leucine, Isoleucine and Valine Metabolism 23.5 8.9 0.011 0.29
ProBetaine Proline betaine Amino‑Acid‑related Xenobiotic − 2.5 1 0.011 0.29
AconAcid Aconitate [cis or trans] Carboxylic acids TCA Cycle 0.3 0.1 0.009 0.29
DG.16.0/18.1 Palmitoyl‑oleoyl‑glycerol Lipid Diacylglycerol 1.7 0.6 0.009 0.29
DG.16.0/18.2 Palmitoyl‑Linoleic acid‑glycerol Lipid Diacylglycerol 1.1 0.4 0.006 0.29
AA Arachidonate (20:4n6) Fatty Acids Long Chain Polyunsaturated Fatty Acid 0.4 0.1 0.003 0.29
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these, triacylglycerols and diacylglycerols contain-
ing C18:1 and C18:2 were enriched in pre-term deliv-
eries (p < 0.01). Gender interaction analysis revealed 
three FDR significant metabolites where the slope of 
the regression line was significantly different between 
males and females in relation to GA at delivery. These 
include the sphingolipids (SM) C24:1 and C16:1 and the 
amino acid-related Taurine (Fig. 4). No significant asso-
ciations were identified between metabolites and other 
adverse pregnancy outcomes, including pre-eclampsia, 
intrauterine fetal death, macrosomia, and maternal 
blood pressure at delivery (data not shown).
Predictive biomarkers association with GDM, DM and GA 
at delivery
We used an extension of the generalized linear model 
that features the elastic net regularization algorithm for 
variable selection, also known as GLMNET in R analy-
sis software. The GLMNET model indicated that Glu 
(beta = 0.09, p = 0.001) was the best predictors of GDM 
Fig. 3 Boxplot of metabolites differentiating Control from DM (GDM + T2DM) groups. A Function enrichment analysis was performed using Fisher’s 
exact test by considering metabolites with a nominal p‑value less than 0.1 from linear regression analysis. p‑value significance level of 0.05 (*) was 
used
Table 3 Metabolites associated with gestational age at delivery
Linear regression was performed to identify significant metabolites associated with pre-term delivery using the R statistical package after correcting for age, BMI and 
principle components (PC1 and PC2). Estimate (beta value), SE, standard error; FDR, False Discovery Rate
Metabolite Biochemical ID Super pathway Sub pathway Estimate SE P value FDR
TG17.2/36.4 TG17:2/36:4 Lipid Triaclylgerol − 0.4 0.1 < 0.001 0.038
DG.18.1/18.1 DG18:1/18:1 Lipid Diacylglycerol − 1.7 0.5 0.002 0.044
DG.18.1/18.2 DG18:1/18:2 Lipid Diacylglycerol − 4.4 1.2 0.001 0.044
DG.18.2/18.2 DG18:2/18:2 Lipid Diacylglycerol − 2.8 0.9 0.002 0.044
TG16.0/36.3 TG16:0/36:3 Lipid Triaclylgerol − 157.6 43.0 0.001 0.044
TG16.1/36.3 TG16:1/36:3 Lipid Triaclylgerol − 12.8 3.8 0.001 0.044
TG18.0/36.3 TG18:0/36:3 Lipid Triaclylgerol − 7.9 2.3 0.001 0.044
TG18.1/34.1 TG18:1/34:1 Lipid Triaclylgerol − 194.1 57.2 0.001 0.044
TG18.1/34.2 TG18:1/34:2 Lipid Triaclylgerol − 132.1 39.4 0.001 0.044
TG18.1/36.1 TG18:1/36:1 Lipid Triaclylgerol − 14.0 4.3 0.002 0.044
TG18.1/36.2 TG18:1/36:2 Lipid Triaclylgerol − 53.1 15.5 0.001 0.044
TG18.1/36.3 TG18:1/36:3 Lipid Triaclylgerol − 61.7 16.2 < 0.001 0.044
TG18.2/34.1 TG18:2/34:1 Lipid Triaclylgerol − 125.3 36.6 0.001 0.044
TG18.2/36.0 TG18:2/36:0 Lipid Triaclylgerol − 1.0 0.3 0.002 0.044
TG18.2/36.1 TG18:2/36:1 Lipid Triaclylgerol − 9.7 3.0 0.002 0.044
TG18.2/36.2 TG18:2/36:2 Lipid Triaclylgerol − 31.2 9.6 0.002 0.044
TG18.2/38.4 TG18:2/38:4 Lipid Triaclylgerol − 1.9 0.5 0.001 0.044
TG20.0/32.4 TG20:0/32:4 Lipid Triaclylgerol − 0.5 0.1 0.002 0.044
TG20.4/36.2 TG20:4/36:2 Lipid Triaclylgerol − 3.7 1.1 0.001 0.044
GCA Glycocholic acid Lipid Bile Acid − 0.2 0.1 0.002 0.046
TG18.0/36.4 TG18:0/36:4 Lipid Triaclylgerol − 3.8 1.2 0.002 0.046
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compared to controls (AUC = 0.81) (Fig. 5a). The model 
also revealed that the phosphatidylcholine diacyl (PC.
aa.C40.2) (beta = − 17.7, p = 0.05), arachidonic acid 
(AA) (beta = 3.2, pp = 0.003), glycochenodeoxycholic 
acid (GCDCA) (beta = 3.4, p = 0.02), and PC.ae.C34.3 
(beta = 0.70 p = 0.02) were the best predictors of all DM 
compared to controls (AUC = 0.90) (Fig. 5b). The model 
also revealed that TG17.2/36.4 (beta = − 2.79, p0.03) and 
TG18.1/34.1 (beta = − 0.006, p = 0.01) were the best pre-
dictors of pre-term delivery (≤ 37  weeks) (AUC = 0.84) 
(Fig. 5c).
Discussion
The diabetes epidemic constitutes a global public health 
challenge. Considering the adverse effects of DM on preg-
nancy outcomes, perinatal morbidity, and development 
of chronic diseases later in life, a better understanding of 
the metabolic mediators underlying these adverse effects 
could potentially provide novel diagnostic and thera-
peutic targets. In this study, targeted metabolomics of 
plasma samples from 67 pregnant women at second tri-
mester was performed. Five metabolites exhibited signifi-
cant differences between controls and T2DM, including 
four amino acids (Asp, Glu, Cit and Ile) and the glycer-
ophospholipid (PC.ae.C34.3), whereas Glu was the only 
metabolite that significantly differentiated DM from con-
trols. Glu was also found to be the best predictor of GDM 
by the GLMNET model confirmed by ROC analysis. The 
model also indicated that PC.aa.C40.2, AA, GCDCA, 
and PC.ae.C34.3 were the best predictors of all DM com-
pared to controls. Our data also indicated that GA at 
delivery was on average 2  weeks earlier in T2DM than 
controls and GDM groups, which correlated negatively 
with HbA1c and SBP and positively with serum albumin 
at second trimester. GLMNET model confirmed by ROC 
Fig. 4 Gender specific associations with gestational age at delivery
Fig. 5 Predictors of GDM, DM and pre‑term delivery. ROC curve indicates the best predictors of GDM (a), DM (b) and pre‑term delivery (c) 
indicating the area under curve (AUC) for each model
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analysis revealed that TG17.2/36.4 and TG18.1/34.1 were 
the best predictors of pre-term delivery (≤ 37 weeks). The 
potential functional relevance of identified metabolites in 
relation to diabetes and pre-term delivery is summarized 
in Table 4.
Metabolic signature of GDM, T2DM and DM 
(GDM + T2DM): In recent years, metabolomics has been 
widely used in the identification of novel pathways and 
specific biomarkers for insulin resistance and T2DM [22, 
30–32]. The data presented here offers a holistic view of 
the changes in plasma metabolites in relation to GDM 
and T2DM in pregnant women in their second trimes-
ter compared to BMI and GA-matched controls. Our 
data revealed no FDR significant differences in metabolic 
profile between GDM and controls, perhaps due to the 
small sample size, although our data indicated that Glu 
was the best predictor of GDM in our study. When we 
combined GDM and T2DM into DM group, significant 
differences in Glu were observed between control and 
DM groups. The elevation in Glu in the DM group was 
previously reported in umbilical vein and artery as well 
as in the plasma of women with GDM compared to nor-
mal pregnant women [33, 34]. Glu is an important excita-
tory neurotransmitter with a potential role in diabetes 
development through excessive activation of N-methyl-
D-aspartate receptors in β-cells and subsequent accel-
eration of β-cell dysfunction and apoptosis induced by 
hyperglycemia [35] (Table  4). Indeed, a previous report 
has indicated that elevated serum glu was associated 
with increased incidents of T2DM in 5  years follow up 
study [36]. Although measurement of a single amino acid 
is unlikely to be sufficient to differentiate controls from 
patients, future studies validating the potential use of 
glu as well as other associated metabolites as predictors 
of GDM before onset and the impact of targeting gluta-
mate to reduce risk of T2DM are warranted. Our data 
also indicated an enrichment of the BCAAs (valine, leu-
cine and isoleucine) in DM compared to controls. Previ-
ous epidemiological studies have indicated that elevated 
levels of circulating BCAAs are associated with insulin 
resistance and T2DM, perhaps because of altered energy 
metabolism or dietary habits [37, 38]. BCAAs were 
shown previously to be involved in several pathways of 
insulin resistance, including fatty acid oxidation, mTOR, 
JNK and IRS1 pathways [39, 40] (Table  4). The phos-
phatidylcholines PC.aa.C40.2 and PC.ae.C34.3 as well as 
AA and GCDCA were identified as the best predictors 
of all DM compared to controls. Similar to our findings, 
previous studies have indicated an inverse relationship 
between acyl-alkyl-phosphatidylcholines C34:3, C40:6, 
C42:5, C44:4, and C44:5 and T2DM risk [35]. Phosphati-
dylcholines are a major constituent of cell membranes. 
They play an important role in membrane-mediated 
cell signaling and Phosphatidylcholine Transfer Protein 
activation of other enzymes. Their decrease in T2DM 
could be due to their role as serum antioxidants prevent-
ing lipoprotein oxidation [41] (Table  4). Additionally, 
elevated arachidonic acid levels during glucose-induced 
insulin release were previously shown to trigger further 
increases in insulin secretion, potentially increasing risk 
of insulin resistance [42] (Table  4). This could explain 
why AA was identified as one of the top predictors of 
DM in our study. Alterations in GCDCA, amongst other 
bile acids, was previously shown to trigger diabetes [43], 
which could also explain why it appeared as one of the 
top predictors of DM in our study (Table 4). When
Table 4 The potential functional relevance of identified metabolites associated with diabetes and pre-term delivery
Glu, glutamate; BCAA, branched chain amino acids; mTOR, The mammalian target of rapamycin; JNK, c-Jun N-terminal kinase; IRS-1, insulin receptor substrate 1; AA, 
arachidonic acid; GCDCA, Glycochenodeoxycholic Acid; DG, diacylglycerols; TG, triacylglycerols
Metabolite Association Potential relevance to pathophysiological aspects 
of diabetes and pre-term delivery
References
Glu Increased in DM Activates N‑methyl‑D‑aspartate receptors in β‑cells, lead‑
ing to acceleration of β‑cell dysfunction and apoptosis 
induced by hyperglycemia
[36]
BCAA (valine, leucine, isoleucine) Increased in DM Promotes insulin resistance by modulating fatty acid oxida‑
tion, mTOR, JNK and IRS1 pathways
[39, 40]
Phosphatidylcholines Decreased in DM Serum antioxidants preventing lipoprotein oxidation [41]
AA Increased in DM Arachidonic acid triggers insulin secretion, potentially 
increasing risk of insulin resistance
[42]
GCDCA Increased in DM Bile acids control gut bacteria overgrowth, species popula‑
tion, and protect the integrity of the intestinal barrier. 
Alterations in GCDCA can trigger diabetes
[43]
DG and TG containing C18:1 and C18:2 Increased in pre‑term delivery Serum linoleic acid is negatively correlated with visceral fat 
accumulation and risk of insulin resistance
[48]
TG17.2/36.4 and TG18.1/34.1 Best predictors of pre‑term delivery Remains to be investigated
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Determinants of pre-term delivery
GA at delivery was on average 2 weeks earlier in T2DM 
than controls and GDM groups. It negatively correlated 
with HbA1c at second trimester, confirming previous 
findings of inverse correlation between HbA1C concen-
tration and length of gestation from early pregnancy to 
mid-3rd  trimester [44]. GA at delivery also correlated 
negatively with SBP at second trimester, which also con-
firmed previous reports of an association between eleva-
tions in SBP in 3rd trimester with spontaneous pre-term 
births [45]. Interestingly, a significant inverse correla-
tion between SBP and gestational age at birth has been 
consistently observed from childhood to adulthood in 
pre-term-born individuals [46]. Our data also showed 
a positive correlation between serum albumin and pre-
term labor. This observation also confirms previous data 
suggesting that woman with higher serum albumin levels 
at the second visit had a longer pregnancy duration, pos-
sibly reflecting better nutritional status [47]. Twenty-two 
metabolites were significantly associated with pre-term 
delivery, including triacylglycerols and diacylglycerols 
containing C18:1 (oleic acid) and C18:2 (linoleic acid). 
Our data agree with previous studies suggesting a nega-
tive correlation between linoleic acid levels and reduc-
tion of insulin resistance [48] (Table  4). The GLMNET 
model revealed that TG17.2/36.4 and TG18.1/34.1 are 
the best predictors of pre-term delivery (≤ 37  weeks). 
Whether these metabolic differences were due to T2DM 
or just gestation age remains to be investigated, as both 
gestational age and T2DM will strongly influence the 
dynamics of metabolites in pregnant women. Further 
quantitative studies will be required to determine if the 
detection of these compounds may be a valuable clinical 
predictor of premature delivery in the second trimester, 
or earlier.
Offspring gender interacting metabolites: Our data 
indicated a significant interaction with offspring gender 
in women with GDM and T2DM as higher proportion 
of female than male offspring were identified in GDM 
participants, but more males than females in T2DM par-
ticipants. Previous studies have found that women car-
rying male fetuses were more likely to have gestational 
diabetes [49, 50]. The results from these studies agree 
with our data from T2DM women but not GDM coun-
terparts, however as the numbers of participating women 
in each group are small, a confirmation in a larger cohort 
is warranted. When considering metabolites that exhibit 
significant association with gender in GDM and T2DM 
women, a number of metabolic differences were identi-
fied in pregnancies with male versus female offspring, 
including specific triglycerides, amino acids and the cho-
lesterol esters. When considering metabolites that show 
gender interaction with GA at delivery, three metabolites 
were identified. These included the sphingolipids (SM) 
C24:1 and C16:1 that exhibited significant opposite 
direction of correlation between males and females, and 
the amino acid-related Taurine that was only significantly 
negatively correlated with GA at delivery in males. The 
functional relevance of these interactions remain to be 
investigated.
Study limitations
The relatively low number of participants per group was 
a main limitation of our study, which was potentially 
responsible for lack of detected differences between 
GDM and the control group; however, multiple signifi-
cant associations were identified between metabolites 
and pre-term delivery. In order to enhance the power 
to identify significant differences between controls and 
DM, GDM and T2DM were combined into one group 
since GDM is associated with both insulin resistance and 
impaired insulin secretion and shares the same risk fac-
tors with T2DM [51]. Additionally, the cross-sectional 
nature of the study limited the assessment of the evolu-
tionary process of metabolites throughout pregnancy and 
the interpretation of the findings from a pathophysiologi-
cal point of view. The observational nature of the findings 
dictates functional validation before suggesting any cau-
salities. Furthermore, since blood samples were collected 
at multiple sites, a batch effect may have occurred, but 
this was mitigated by standardized protocols for sample 
collection, processing and storage. It is possible that other 
unmeasured factors may have influenced our data includ-
ing dietary habits, medication/supplements and other 
unknown environmental factors; however, inclusion 
of principle components in the regression model may 
have captured part of these potential confounding fac-
tors. Finally, due to the limited sample size, splitting the 
cohort into testing and validation was not possible, there-
fore the ROC curve analysis was used on the full data-
set to examine the discriminatory ability of metabolites 
that were detected as significant from regression analysis 
based on the same data. A more rigorous validation of 
the results is warranted and requires a separate cohort. 
Large cohorts, dynamic monitoring of metabolites dur-
ing pregnancy, and analyses of various specimen types 
could improve our understanding of metabolites altera-
tion and verify the validity of multi-marker predictive 
models of GDM and pre-term labor. Such dynamic moni-
toring would also enable further mitigation of the impact 
on these metabolic changes on both mothers and their 
fetuses. Furthermore, comparing short and long-term 
post-delivery effects would provide additional support 
for measurement of critical biomarkers and development 
of guidelines and methods to mitigate these effects.
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Conclusion
Our data provided a comprehensive overview of metabo-
lite alteration in women in their second trimester, with 
metabolic profiling identifying significant associations 
between a number of metabolites and T2DM/GDM 
patients including glutamate, branched chair amino 
acids, phosphatidylcholines and certain triglycerides. 
Future studies are warranted to confirm and validate 
these markers in large cohorts and different ethnici-
ties and to study their potential utilization for targeted 
therapies.
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